NCT04586335 2024-03-21Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.Haihe Biopharma Co., Ltd.Phase 1 Terminated24 enrolled
NCT04330625 2022-11-08Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)Duke UniversityPhase 1 Terminated1 enrolled